Lantern Pharma announced the launch of an AI Center of Excellence in Bengaluru, India, to industrialize its proprietary RADR platform and accelerate global development opportunities with biopharma partners.
The new center will focus on scaling the RADR AI engine, which currently powers oncology drug discovery with over 60 billion data points and is expected to reach 100 billion. The expansion will also extend the platform to other disease areas, broadening Lantern’s therapeutic reach.
Lantern said the center will be cash‑flow neutral, with initial hiring of data scientists, software engineers, and operations staff. The move taps into India’s growing biotech ecosystem and talent pool, enabling follow‑the‑sun development cycles and cost efficiencies.
CEO Panna Sharma emphasized that the center represents the industrialization of Lantern’s vision, scaling proven RADR capabilities to serve pharmaceutical partners seeking precision, data‑guided therapies across oncology and beyond. Board member Dr. Vijay Chandru highlighted the convergence of AI, genomics, and clinical data as a transformative force.
Lantern will use the center to open collaboration channels with Indian biopharma companies and to support its broader goal of commercializing RADR modules beyond its internal pipeline. The company has scheduled an Investor and Analyst Day on January 22 to discuss the initiative and platform rollout.
The announcement signals Lantern’s commitment to scaling AI‑driven drug discovery, positioning it ahead of competitors and reinforcing its strategy to monetize the RADR platform through partnerships and new disease indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.